Given its central role in cancer, PI3K has become a significant target for cancer therapy. Several PI3K inhibitors have been developed and are in various stages of clinical trials. These inhibitors aim to block the kinase activity of PI3K, thereby inhibiting the downstream signaling pathways that drive cancer cell proliferation and survival. Examples of PI3K inhibitors include idelalisib, used for certain types of lymphoma, and alpelisib, approved for use in combination with fulvestrant for HR-positive, HER2-negative breast cancer with PIK3CA mutations.
